Evidence map›Paper›PMID 36675083›Full record

ArticleInternational journal of molecular sciences2023

Development of In Vitro Dry Eye Models to Study Proliferative and Anti-Inflammatory Effects of Allogeneic Serum Eye Drops.

Silja Voß, Till Behrmann, Stephan Reichl

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Lute-GenAntioxidants (Basel, Switzerland) · 2026
    Article
  2. Review
  3. Article
  4. Blood Derivatives in the Therapy of Ocular Surface Diseases.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Silja VoßInstitut für Pharmazeutische Technologie und Biopharmazie, Mendelssohnstraße 1, Technische Universität Braunschweig, 38106 Braunschweig, Germany.
Till BehrmannInstitut für Pharmazeutische Technologie und Biopharmazie, Mendelssohnstraße 1, Technische Universität Braunschweig, 38106 Braunschweig, Germany.
Stephan ReichlInstitut für Pharmazeutische Technologie und Biopharmazie, Mendelssohnstraße 1, Technische Universität Braunschweig, 38106 Braunschweig, Germany.ORCID 0000-0001-8344-9070
Technische Universität Braunschweig · DE

Funding

European Regional Development Fund ZW3 - 85027860
6 · The paper itself

Abstract

This study aimed to develop valid in vitro models for preclinical evaluation of proliferative and anti-inflammatory effects of human allogeneic serum eye drops for dry eye disease (DED) treatment. A DED wound healing model was developed by analyzing the influence of coating and serum concentrations on human corneal epithelial (HCE-T) wound closure. Further, intralaboratory variance, freeze-thaw cycle effects, donor variability and stability assays were conducted. Interleukin-1β (IL-1β) and tumor necrosis factor α (TNFα) were used to induce the gene expression of matrix metalloproteinase 9 (MMP9), cyclooxygenase 2 (COX2), transforming growth factor-β (TGFβ) and IL-1β. MMP9 induction was optimized using a design-of-experiments (DoE) approach and applied to examine serum under static and dynamic conditions. MMP9 protein expression was analyzed by ELISA. The DED wound healing model detected proliferative effects of serum down to 1% with a small intralaboratory variance. Serum stability was shown over six months, donor variance could be detected, and freeze-thaw cycle effects did not affect wound closure. Serum decreased MMP9 expression on the gene and protein levels. The induction method was successfully optimized using DoE modeling and transferred to a dynamic setting mimicking tear film fluidics. The DED wound healing and inflammatory DED model present useful in vitro models for the preclinical evaluation of allogeneic serum eye drops without the use of animal experiments.

Indexed as

Corneal InjuriesDry Eye SyndromesHematopoietic Stem Cell TransplantationAnimalsAnti-Inflammatory AgentsHumansMatrix Metalloproteinase 9Ophthalmic SolutionsTearsAnti-Inflammatory AgentsMatrix Metalloproteinase 9Ophthalmic Solutionsallogeneic serumdesign of experimentsdry eyedynamic flow systemin vitro modelmatrix metalloprotease 9wound healing

Identifiers

PMID36675083
PMCPMC9864688
OpenAlexW4316040098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.